// App-Quantinova.ai

544 : First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Researchers

Presenter

  • Jose Manuel Ruiz Morales

Principal Investigators

  • Frede Donskov

  • Georg A. Bjarnason

  • Jae-Lyun Lee

  • Jennifer J. Knox

  • Benoit Beuselinck

  • Ulka N. Vaishampayan

  • James Brugarolas

  • Reuben James Broom

  • Aristotelis Bamias

  • Takeshi Yuasa

  • Sandhya Srinivas

  • D. Scott Ernst

  • Carmel Jo Pezaro

  • Lori Wood

  • Christian K. Kollmannsberger

  • Brian I. Rini

  • Toni K. Choueiri

  • Daniel Yick Chin Heng

Medical Centers

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Auckland City Hospital, Auckland, New Zealand

  • Dept of Clinical Therapeutics, University of Athens, Athens, Greece

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • Stanford Univeresity Medical Center, Stanford, CA

  • London Regional Cancer Centre, London, ON, Canada

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Dana-Farber Cancer Institute, Boston, MA

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

Locations

  • Canada

  • Denmark

  • Republic of South Korea

  • Belgium

  • United States

  • New Zealand

  • Greece

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pazopanib

  • Sunitinib

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved